Keryx Biopharmaceuticals (NASDAQ:KERX) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 17,498,249 shares, a decrease of 20.3% from the April 28th total of 21,948,085 shares. Based on an average daily volume of 2,126,582 shares, the days-to-cover ratio is presently 8.2 days. Currently, 16.4% of the company’s stock are short sold.

Separately, Maxim Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Keryx Biopharmaceuticals in a report on Monday, May 1st. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.16.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 6.46 on Friday. The stock’s market capitalization is $700.69 million. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $7.80. The stock has a 50 day moving average price of $6.13 and a 200-day moving average price of $5.76.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative net margin of 584.76% and a negative return on equity of 270.26%. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.19 million. During the same period in the previous year, the company earned ($0.39) EPS. Keryx Biopharmaceuticals’s revenue was up 73.2% compared to the same quarter last year. On average, analysts forecast that Keryx Biopharmaceuticals will post ($0.69) earnings per share for the current year.

Several large investors have recently bought and sold shares of the stock. Green Square Capital LLC bought a new stake in Keryx Biopharmaceuticals during the third quarter valued at approximately $135,000. Endurant Capital Management LP bought a new stake in Keryx Biopharmaceuticals during the third quarter valued at approximately $616,000. Knoll Capital Management LP bought a new stake in Keryx Biopharmaceuticals during the third quarter valued at approximately $1,030,000. Marco Investment Management LLC boosted its stake in Keryx Biopharmaceuticals by 6.5% in the third quarter. Marco Investment Management LLC now owns 49,350 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 3,000 shares in the last quarter. Finally, Iridian Asset Management LLC CT bought a new stake in Keryx Biopharmaceuticals during the fourth quarter valued at approximately $1,339,000. 61.74% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Short Interest in Keryx Biopharmaceuticals (KERX) Declines By 20.3%” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/27/short-interest-in-keryx-biopharmaceuticals-kerx-declines-by-20-3.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

12 Month Chart for NASDAQ:KERX

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.